CX Institutional Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

CX Institutional trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.3% during the 4th quarter, Holdings Channel reports. The fund owned 3,232 shares of the medical research company’s stock after selling 112 shares during the period. CX Institutional’s holdings in Charles River Laboratories International were worth $597,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of CRL. Wellington Management Group LLP raised its holdings in shares of Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after acquiring an additional 3,738,018 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after purchasing an additional 509,163 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Charles River Laboratories International by 73.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 239,913 shares of the medical research company’s stock valued at $49,561,000 after buying an additional 101,732 shares during the period. Mizuho Securities USA LLC raised its holdings in Charles River Laboratories International by 2,336.4% during the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock valued at $19,081,000 after buying an additional 92,895 shares during the period. Finally, Premier Fund Managers Ltd raised its holdings in Charles River Laboratories International by 56.3% during the 3rd quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock valued at $49,573,000 after buying an additional 90,000 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRL has been the topic of several recent research reports. Redburn Atlantic initiated coverage on Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Evercore ISI raised their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, Citigroup downgraded Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and a consensus target price of $204.38.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $164.88 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The business’s 50 day moving average price is $186.75 and its 200-day moving average price is $197.21. The firm has a market capitalization of $8.43 billion, a PE ratio of 20.64, a P/E/G ratio of 5.94 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1 year low of $160.85 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the previous year, the company posted $2.72 earnings per share. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).